INmune Bio Inc (INMB) - Net Assets
Based on the latest financial reports, INmune Bio Inc (INMB) has net assets worth $20.36 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($26.84 Million) and total liabilities ($6.48 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is INmune Bio Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $20.36 Million |
| % of Total Assets | 75.85% |
| Annual Growth Rate | N/A |
| 5-Year Change | -70.68% |
| 10-Year Change | N/A |
| Growth Volatility | 48.89 |
INmune Bio Inc - Net Assets Trend (2015–2025)
This chart illustrates how INmune Bio Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of INmune Bio Inc.
Annual Net Assets for INmune Bio Inc (2015–2025)
The table below shows the annual net assets of INmune Bio Inc from 2015 to 2025. Also explore how fast is INmune Bio Inc growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $23.52 Million | -26.71% |
| 2024-12-31 | $32.10 Million | -15.84% |
| 2023-12-31 | $38.14 Million | -36.54% |
| 2022-12-31 | $60.10 Million | -25.08% |
| 2021-12-31 | $80.22 Million | +107.01% |
| 2020-12-31 | $38.75 Million | +64.14% |
| 2019-12-31 | $23.61 Million | +42.75% |
| 2018-12-31 | $16.54 Million | -8.64% |
| 2017-12-31 | $18.10 Million | +12233.64% |
| 2016-12-31 | $-149.20K | -690.77% |
| 2015-12-31 | $-18.87K | -- |
Equity Component Analysis
This analysis shows how different components contribute to INmune Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20898813200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $27.00K | 0.11% |
| Other Comprehensive Income | $-737.00K | -3.13% |
| Other Components | $233.27 Million | 991.63% |
| Total Equity | $23.52 Million | 100.00% |
INmune Bio Inc Competitors by Market Cap
The table below lists competitors of INmune Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MacroWell OMG Digital Entertainment Co Ltd
TWO:3687
|
$57.89 Million |
|
Ma Kuang Healthcare Holding Ltd
TWO:4139
|
$57.90 Million |
|
Sam-A Pharm. Co. Ltd
KQ:009300
|
$57.91 Million |
|
Arlitech Electronic
TWO:6432
|
$57.93 Million |
|
Chilwa Minerals Ltd
AU:CHW
|
$57.86 Million |
|
T7 Global Bhd
KLSE:7228
|
$57.81 Million |
|
Univentures Public Company Limited
BK:UV
|
$57.81 Million |
|
NTPM Holdings Bhd
KLSE:5066
|
$57.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INmune Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 32,097,000 to 23,524,000, a change of -8,573,000 (-26.7%).
- Net loss of 45,933,000 reduced equity.
- New share issuances of 27,544,000 increased equity.
- Other comprehensive income decreased equity by 162,000.
- Other factors increased equity by 9,978,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-45.93 Million | -195.26% |
| Share Issuances | $27.54 Million | +117.09% |
| Other Comprehensive Income | $-162.00K | -0.69% |
| Other Changes | $9.98 Million | +42.42% |
| Total Change | $- | -26.71% |
Book Value vs Market Value Analysis
This analysis compares INmune Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.46x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.00 | $2.18 | x |
| 2016-12-31 | $-0.03 | $2.18 | x |
| 2017-12-31 | $1.61 | $2.18 | x |
| 2018-12-31 | $1.47 | $2.18 | x |
| 2019-12-31 | $2.30 | $2.18 | x |
| 2020-12-31 | $3.23 | $2.18 | x |
| 2021-12-31 | $4.97 | $2.18 | x |
| 2022-12-31 | $3.35 | $2.18 | x |
| 2023-12-31 | $2.12 | $2.18 | x |
| 2024-12-31 | $1.61 | $2.18 | x |
| 2025-12-31 | $0.88 | $2.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently INmune Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -195.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -91866.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.38x
- Recent ROE (-195.26%) is below the historical average (-57.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-46.98K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-262.08K |
| 2017 | -4.59% | 0.00% | 0.00x | 1.02x | $-2.64 Million |
| 2018 | -75.21% | 0.00% | 0.00x | 1.05x | $-14.09 Million |
| 2019 | -32.52% | -9.88% | 3.17x | 1.04x | $-10.04 Million |
| 2020 | -31.22% | -110838.76% | 0.00x | 1.05x | $-15.97 Million |
| 2021 | -37.82% | -16762.43% | 0.00x | 1.25x | $-38.36 Million |
| 2022 | -47.66% | -7659.63% | 0.00x | 1.36x | $-34.66 Million |
| 2023 | -78.68% | -19360.00% | 0.00x | 1.49x | $-33.82 Million |
| 2024 | -131.11% | -300585.71% | 0.00x | 1.23x | $-45.29 Million |
| 2025 | -195.26% | -91866.00% | 0.00x | 1.38x | $-48.29 Million |
Industry Comparison
This section compares INmune Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INmune Bio Inc (INMB) | $20.36 Million | 0.00% | 0.32x | $57.87 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About INmune Bio Inc
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of pati… Read more